[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619004":3},{"organization":4,"outcomesModule":7,"designInfo":38,"detailedDescription":37,"studyPopulation":37,"armGroups":45,"interventions":57,"overallOfficials":37,"centralContacts":69,"locations":76,"responsibleParty":90,"collaborators":94,"id":96,"slug":37,"hasResults":97,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":37,"eligibilityCriteria":101,"healthyVolunteers":97,"sex":102,"minAge":103,"maxAge":37,"enrollmentInfo":104,"targetDuration":37,"studyType":107,"phases":108,"briefSummary":110,"conditions":111,"keywords":113,"overallStatus":120,"whyStopped":37,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":130},{"fullName":5,"class":6},"British Columbia Cancer Agency","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":37},[9],{"measure":10,"description":11,"timeFrame":12},"Assess Overall-Survival in time-of-day administration of ICI\u002FICI treatment","To assess overall survival (OS) in patients treated with time-of day dependent administration of nivolumab-ipilimumab (ICI\u002FICI) standard-of-care therapy in advanced kidney cancer. OS is defined as the time from randomization to death from any cause. The primary analysis will compare OS curves between study arms and estimate 2-year OS rates for each group.","From enrollment to the end of follow-up at 24 months.",[14,18,21,24,27,31,34],{"measure":15,"description":16,"timeFrame":17},"Determine Objective Response Rate in time-of-day administration of ICI\u002FICI treatment","Objective response rate (ORR) will be determined by Proportion of patients achieving a complete or partial response as assessed by RECIST v1.1 criteria, confirmed by central or investigator review. Tumor assessments will be performed as standard of care (typically every 12 weeks), and best overall response prior to disease progression will be used for ORR determination.","From enrollment to the end of follow-up at 24-months.",{"measure":19,"description":20,"timeFrame":17},"Evaluate Progression-Free Survival in time-of-day administration of ICI\u002FICI treatment","Progression-free Survival (PFS) will be determined by time of randomization to disease progression or death from any cause.",{"measure":22,"description":23,"timeFrame":17},"Determine the Time-to-Treatment Failure in time-of-day administration of ICI\u002FICI treatment","Time to treatment failure (TTF) is determined by assessing time from treatment initiation to treatment discontinuation for any reason, including disease progression, unacceptable toxicity, patient withdrawal, or death, capturing both treatment efficacy and tolerability.",{"measure":25,"description":26,"timeFrame":17},"Assess treatment-related tolerability and toxicity differences","Differences in steroid use (yes\u002Fno) for the management of treatment-related toxicity, treatment interruptions (yes\u002Fno) due to treatment-related toxicity, and treatment discontinuations (yes\u002Fno) due to treatment-related toxicity will be used as surrogate safety outcomes, as comprehensive adverse event documentation is beyond the scope of this pragmatic clinical trial. The study seeks to determine whether treatment administration at a predefined time of day is associated with differences in the need for toxicity-related clinical interventions. Given that the relevant adverse events are well characterized in the existing literature, the focus of this study is on comparative safety between groups using these surrogate measures rather than on detailed characterization of individual adverse events.",{"measure":28,"description":29,"timeFrame":30},"Immune Profiling","Immune cell populations will be characterized from the blood samples at baseline (prior to treatment initiation) and at three predefined time points during therapy: 1 day after treatment initiation, 3 weeks into treatment, and 12 weeks into treatment. Cytometry by time-of-flight (CyTOF) will be used to comprehensively profile immune cell populations allowing for high-dimensional assessment of immune cell composition and activation states across treatment timing groups.","At 4 time points: Baseline, 1-day post first cycle of treatment, 3 weeks into treatment and 12 weeks into treatment",{"measure":32,"description":33,"timeFrame":30},"Bulk RNA sequencing (RNA-seq)","Bulk RNA sequencing (RNA-seq) will be performed to comprehensively characterize global gene expression profiles and to evaluate time-of-day-associated differences in immune-related transcriptional signatures. This approach will enable the identification of circadian variation in gene expression and provide insight into temporal regulation of immune pathways in response to treatment.",{"measure":35,"description":36,"timeFrame":30},"Cytokine and chemokine analyses","Plasma will be isolated for cytokine and chemokine analyses to assess systemic immune signaling and inflammatory profiles. Quantitative evaluation of circulating cytokines and chemokines will provide insight into treatment- and time-dependent changes in immune activation, inflammation, and immune regulation, complementing cellular and transcriptional immune profiling.",null,{"allocation":39,"interventionModel":40,"interventionModelDescription":41,"primaryPurpose":42,"observationalModel":37,"timePerspective":37,"maskingInfo":43},"RANDOMIZED","PARALLEL","This study is a randomized, controlled trial designed to evaluate the effects of timing of standard-of-care (SOC) treatment administration on patient outcomes. Participants will be randomly assigned to receive SOC nivolumab\u002Fipilimumab either in the morning or in the afternoon, with no additional interventions planned. Patients will be scheduled for treatments at the same time for the first four cycles, with a ±1 hour flexibility, to minimize the impact of timing as a confounding factor in the analyses. The trial is open-label and not blinded due to the nature of the intervention (timing of treatment).","TREATMENT",{"masking":44,"maskingDescription":37,"whoMasked":37},"NONE",[46,52],{"label":47,"type":48,"description":49,"interventionNames":50},"Arm A: Morning ICI\u002FICI Treatment","ACTIVE_COMPARATOR","Participants will receive standard-of-care therapy (ICI\u002FICI) administered in the morning (before 11:30am).",[51],"Drug: Nivolumab & Ipilimumab",{"label":53,"type":48,"description":54,"interventionNames":55},"Arm B: Afternoon ICI\u002FICI Treatment","Participants will receive standard-of-care therapy (ICI\u002FICI) administered in the afternoon (after 1:30pm).",[56],"Drug: Nivolumab + Ipilimumab",[58,65],{"type":59,"name":60,"description":61,"armGroupLabels":62,"otherNames":63},"DRUG","Nivolumab & Ipilimumab","Participants will receive ICI\u002FICI as part of their standard-of-care therapy administered in the morning before 11:30am (Arm A) , as determined by randomization.",[47],[64],"ICI\u002FICI",{"type":59,"name":66,"description":67,"armGroupLabels":68,"otherNames":37},"Nivolumab + Ipilimumab","Participants will receive ICI\u002FICI as part of their standard-of-care therapy administered in the afternoon after 1:30pm (Arm B) , as determined by randomization.",[53],[70],{"name":71,"role":72,"phone":73,"phoneExt":74,"email":75},"Dr. Guliz Ozgun, MD","CONTACT","604-877-6000","676213","guliz.ozgun@bccancer.bc.ca",[77],{"facility":78,"status":37,"city":79,"state":80,"zip":81,"country":82,"countryCode":83,"cosmosGeoPoint":84,"geoPoint":89,"contacts":37},"BC Cancer - Vancouver Cancer Centre","Vancouver","British Columbia","V5Z 4E6","Canada","CA",{"type":85,"coordinates":86},"Point",[87,88],-123.11934,49.24966,{"lat":88,"lon":87},{"type":91,"investigatorFullName":92,"investigatorTitle":93,"investigatorAffiliation":5,"oldNameTitle":37,"oldOrganization":37},"SPONSOR_INVESTIGATOR","Guliz Ozgun","Medical Oncologist, Principal Investigator",[95],{"name":5,"class":6},"100619004",false,"NCT07338981","The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI\u002FICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.","(CHRONO-RCC) Time-of-day-Dependent Administration of Dual Immune Check Point Inhibitors (ICI) in Advanced Kidney Cancer","Inclusion Criteria:\n\nParticipants must meet all of the following criteria to be eligible for participation in this trial. Waivers to the inclusion criteria will NOT be allowed.\n\n1. Age 18 or older\n2. Able to provide informed consent\n3. Histologically confirmed advanced clear cell kidney cancer\n4. Eligible for standard-of-care nivolumab\u002Fipilimumab regimen\n5. Measurable disease per RECIST 1.1\n6. ECOG performance status 0-2\n7. Ability to adhere to scheduled infusion times (Before 11:30 a.m. or after 1:30 pm)\n\nExclusion Criteria:\n\nParticipants are excluded from the trial if any of the following criteria apply. Waivers to the exclusion criteria will NOT be allowed.\n\n1. Non-clear cell RCC histology\n2. Concurrent malignancy requiring active systemic therapy, unless disease-free for at least 2 years\n3. Inability to comply with protocol-specified infusion timing for the first 4 cycles\n4. Night shift workers\n5. Clinical evidence of new or enlarging brain metastasis or carcinomatous meningitis\n6. Known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the trial\n7. Patients who have traveled across ≥2 time zones within the past 14 days prior to randomization will be excluded, due to potential disruption of circadian rhythms (jet lag), which may affect chronotherapy-related endpoints.\n8. Patients with a clinically diagnosed sleep disorder, including but not limited to insomnia, obstructive sleep apnea, restless leg syndrome, or circadian rhythm sleep-wake disorders, that is moderate to severe, untreated, or poorly controlled, will be excluded.","ALL","18 Years",{"count":105,"type":106},142,"ESTIMATED","INTERVENTIONAL",[109],"PHASE3","The goal of this clinical trial is to learn if the timing of treatments plays a role in how effective the standard-of-care drugs nivolumab\u002Fipilimumab (ICI\u002FICI) works to treat adults with advanced kidney cancer. The trial will also learn if time-of-day reduces ICI\u002FICI side-effects. Researchers will compare ICI\u002FICI given in the morning (before 11:30am) vs in the afternoon (after 1:30pm), to see if circadian rhythm effects how ICI\u002FICI works to treat advanced kidney cancer. Participants will be randomized in Arm A or Arm B to receive drugs ICI\u002FICI either in the morning (Arm A) or afternoon (Arm B) as part of their standard-of-care treatment for advanced kidney cancer. Participants will:\n\n* Visit the clinic either in the morning (Arm A) or afternoon (Arm B) to receive ICI\u002FICI treatment as part of their regular medical care for advanced kidney cancer\n* Frequency of visits will follow standard-of-care guidelines",[112],"Advanced Kidney Cancer",[114,115,116,117,118,119],"Chronoimmunotherapy","Time-of-day administration","Chronotherapy","Circadian rhythm","Advanced kidney cancer","Nivolumab\u002FIpilimumab","NOT_YET_RECRUITING","2026-01-07",{"date":123,"type":124},"2026-01-14","ACTUAL",{"date":126,"type":106},"2026-04",{"date":128,"type":106},"2032-12",{"name":92,"class":6},1]